

Atty. Docket No.: 11111/2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, et al.
Serial No.: 10/645,000
Filed: August 20, 2003
Entitled: LECTIN COMPOSITIONS AND
METHODS FOR MODULATING
AN IMMUNE RESPONSE TO AN
ANTIGEN

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Conf. No.: Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 11111/2002. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: September 16, 2003

Name: Mark J. FitzGerald


Registration No.: 45,928

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 11111/2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, et al.
Serial No.: 10/645,000
Filed: August 20, 2003
Entitled: LECTIN COMPOSITIONS AND
METHODS FOR MODULATING
AN IMMUNE RESPONSE TO AN
ANTIGEN

Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Conf. No.: Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: September 16, 2003

Respectfully submitted,

Name: Mark J. FitzGerald
Registration No.: 45,928
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 11111/2002		Serial No. 10/645,000	
INFORMATION DISCLOSURE STATEMENT		Applicant(s): Segal, et al.			
		Filing Date: August 20, 2003		Group: Not Yet Assigned	
U.S. PATENT DOCUMENTS					
Examiner Initial		Patent No.	Date	Name	Class Subclass Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS					
Examiner Initial		Document No.	Publication Date	Country	Class Subclass Translation
					YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)					
	1.	Faulkner, L. et al., (2001), "IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells", <i>International Immunology</i> , 13(6):713-721			
	2.	Batova, A. et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ", <i>Clinical Cancer Research</i> , 5:4259-4263.			
	4.	Frankel, A. et al., (1995), "IL2-Ricin Fusion Toxin Is Selectively Cytotoxic <i>in Vitro</i> to IL2 Receptor-Bearing Tumor Cells", <i>Bioconjugate Chem.</i> , 6:666-672.			
	4.	Gillies, S.D. et al., (1992), "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1428-1432.			
	5.	Barker, E. et al., (1991), "Effect of a Chimeric Anti-Ganglioside G _{D2} Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells", <i>Cancer Research</i> , 51:144-149.			
	6.	Gillies, S.D. et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody" <i>Hybridoma</i> , 10(3):347-356.			
EXAMINER				DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>**Copies of references not provided at the time of this submission.</p>					